By Kelly Cloonan

American depositary receipts of Legend Biotech gained after the company said it observed promising early clinical evidence for a therapy aimed at treating non-Hodgkin lymphoma.

ADRs climbed 40% to $35.60 on Tuesday, and are now up 64% year to date.

In an ongoing Phase 1 study of 12 patients with relapsed or refractory B-cell non-Hodgkin lymphoma, Legend Biotech's CAR-T cell therapy LB2501 demonstrated a 100% objective response rate and an 83% complete response rate.

The company said the data supports the potential of an in vivo CAR-T approach in B-cell malignancies. LB2501 is designed to generate CAR-T cells directly within a patient following an intravenous infusion, eliminating the need for cell manufacturing and lymphodepletion, the company said.

"By generating CAR-T cells directly within the patient, this approach has the potential to simplify treatment delivery and expand access for patients who may not be able to receive traditional CAR-T cell therapies," Chief Executive Ying Huang said.

Non-Hodgkin lymphoma is one of the most common types of cancers in the U.S. The American Cancer Society estimates about 79,320 people will be diagnosed with non-Hodgkin lymphoma in 2026, and about 19,970 people will die from it.

B-cell lymphomas account for about 85% of NHL cases, Legend Biotech said.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

June 02, 2026 13:58 ET (17:58 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.